ALPPL2 is a potential diagnostic biomarker for pancreatic cancer derived extracellular vesicles

Shin, H-S.; Jung, S.B.; Park, S.; Dua, P.; Lee, D-k.

dc.contributor.author	Shin, H-S.
dc.contributor.author	Jung, S.B.
dc.contributor.author	Park, S.
dc.contributor.author	Dua, P.
dc.contributor.author	Lee, D-k.
dc.date.accessioned	2019-09-18T04:57:38Z
dc.date.available	2019-09-18T04:57:38Z
dc.date.issued	2019
dc.identifier.citation	Molecular Therapy - Methods & Clinical Development. 15; 2019; 204-210.	en_US
dc.identifier.uri	https://doi.org/10.1016/j.omtm.2019.08.016
dc.identifier.uri	http://irgu.unigoa.ac.in/drs/handle/unigoa/5853
dc.description.abstract	Pancreatic cancer is an aggressive malignancy that often goes undiagnosed in the early stages. Non-invasive, early and accurate diagnosis is therefore undoubtedly the "holy grail" of pancreatic cancer research. However, despite extensive research efforts, there is no definitive biomarker for this cancer. Previously, we identified Alkaline phosphatase placental-like 2 (ALPPL2) as a diagnostic biomarker for pancreatic ductal adenocarcinoma and developed a 2'- fluoro modified RNA aptamer towards it. In this study, we show that ALPPL2 is present in pancreatic cancer extracellular vesicles (EVs), and therefore has potential application in liquid biopsy-based diagnostic strategies. We also developed ALPPL2 direct and sandwich aptamer-linked immobilized sorbent assay (ALISA) for EVs, which could sensitively and specifically detect the protein. We believe that our ALISA format may have a potential diagnostic utility in screening pancreatic cancer derived EVs.	en_US
dc.publisher	Cell Press	en_US
dc.subject	Microbiology	en_US
dc.title	ALPPL2 is a potential diagnostic biomarker for pancreatic cancer derived extracellular vesicles	en_US
dc.type	Journal article	en_US
dc.identifier.impf	y